News & Updates

Tirzepatide FDA Approval for Cardiovascular Risk

The FDA approved Mounjaro (tirzepatide) on August 28, 2026 to cut MACE risk 8% versus dulaglutide in the 13,299-person SURPASS-CVOT trial, for type 2 diabetes patients at high cardiovascular risk.

GLP-1 Drugs and Cancer Risk

A 160,000-patient 2026 study found GLP-1 use linked to a 41% lower risk of obesity-associated cancers.

Foundayo Wins UK Approval

The MHRA approved Foundayo (orforglipron) on August 10, 2026, the first European authorization for the drug. Not yet on the NHS, and nothing changes for US patients already on it.

Is Retatrutide a Biologic? The FDA Lawsuit

A federal judge vacated the FDA's classification of retatrutide as a drug in September 2025. Lilly has appealed, and oral arguments land September 24, 2026, with 7 years of exclusivity and future compounding rights on the line.

Is Compounded Semaglutide Legal in 2026?

503B bulk compounding of semaglutide ended February 21, 2025. The FDA proposed a permanent exclusion April 30, 2026, but no final rule has published since the comment period closed June 29.

Retatrutide and Knee Osteoarthritis: TRIUMPH-4

TRIUMPH-4: retatrutide cut knee osteoarthritis pain 75.8% and produced 28.7% weight loss at 68 weeks.

GLP-1s and Muscle Loss

How much GLP-1 weight loss is muscle, and how to protect it.

Novo Nordisk Sues Eli Lilly Over Wegovy vs Zepbound Ads

Novo Nordisk sued Eli Lilly on July 21, 2026, saying Zepbound ads cite an outdated 33 lb Wegovy figure instead of the newer 7.2mg dose's 47 lb average.

Retatrutide TRIUMPH-2 and TRIUMPH-3 Results

TRIUMPH-2 and TRIUMPH-3 hit up to 20.8% and 22.6% weight loss in diabetes and heart disease patients, but the cardiovascular event data was not statistically significant.

FDA Panel Backs Semax, Epitalon, Rejects Emideltide

The FDA's advisory committee voted 8-5 for Semax and 7-4 for Epitalon on July 24, 2026, then rejected Emideltide 6-7, the only no vote across all seven peptides reviewed.

FDA Panel Votes to Recommend BPC-157 for Compounding

The FDA's advisory committee voted 8-6 on July 23, 2026 to recommend BPC-157, KPV, TB-500, and MOTS-c for the compounding list, overruling FDA staff's own recommendation.

Retatrutide for Type 2 Diabetes: TRANSCEND-T2D-1

TRANSCEND-T2D-1: retatrutide cut A1C by up to 2.0 points and produced up to 16.8% weight loss in 537 adults with type 2 diabetes over 40 weeks.

FDA Peptide Panel Conflict of Interest

STAT and CNN reporting found several new FDA panel members voting July 23-24 on BPC-157 and TB-500 run or promote peptide businesses themselves.

BPC-157 and TB-500: FDA Hearing July 2026

The FDA Pharmacy Compounding Advisory Committee will review BPC-157, TB-500, and 5 other peptides for the 503A compounding list on July 23-24, 2026.

FDA Staff Recommend Against BPC-157, TB-500

FDA briefing documents posted June 30, 2026 recommend against adding BPC-157, TB-500, and 5 other peptides to the 503A compounding list.

Generic Tirzepatide: FDA Review and Patent Timeline

Sandoz and Amneal both filed ANDAs for generic tirzepatide in 2026, but Eli Lilly patents run to 2036. Here is what FDA acceptance actually means.

CagriSema for Type 2 Diabetes: REIMAGINE Results

REIMAGINE 2: CagriSema cut HbA1c 1.91 points more than semaglutide alone and produced 14.2% weight loss in 2,728 adults with type 2 diabetes.

What Is Aleniglipron?

Structure Therapeutics' oral GLP-1 pill posted 16.3% placebo-adjusted weight loss in Phase 2 ACCESS II with no fasting window required.

Is Compounded Tirzepatide Legal in 2026?

FDA proposed April 30 to permanently ban 503B bulk compounding of tirzepatide and semaglutide. Comment period closes June 29. 503A window remains narrow.

Survodutide MASLD Phase 3 Results

SYNCHRONIZE-MASLD: survodutide normalized liver fat in 61% of patients with fatty liver disease at 48 weeks.

CagriSema vs Tirzepatide

REDEFINE 4: tirzepatide won 25.5% to 23% at 84 weeks, and CagriSema failed to meet the non-inferiority threshold.

GLP-1 Hair Loss: Tirzepatide vs Semaglutide

2026 TriNetX cohort: tirzepatide RR 1.68, semaglutide RR 1.43 for nonscarring hair loss vs metformin. Mechanism, timeline, and what helps.

Berobenatide: Once-Monthly GLP-1 Shot

Pfizer's berobenatide posted 12.3% placebo-adjusted weight loss with monthly maintenance dosing in Phase 2b VESPER trials at ADA 2026.

Wegovy HD: Semaglutide 7.2mg Results

STEP UP trial: semaglutide 7.2mg delivered 20.7% weight loss, closing the gap with tirzepatide.

Survodutide SYNCHRONIZE-1 Results

SYNCHRONIZE-1: 16.6% weight loss, 34% less visceral fat, 63% less liver fat in 76-week Phase 3 trial.

GLP-1 Drugs and Heart Failure

SOUL trial: oral semaglutide cut MACE by 14% and heart failure events by 22% in 9,647 high-risk T2D patients.

GLP-1 Drugs and Alzheimer's

EVOKE and EVOKE+ enrolled 3,808 people for two years: oral semaglutide made no difference on Alzheimer's progression.

Medicare GLP-1 Coverage Starting July 2026

The Medicare GLP-1 Bridge covers Wegovy, Zepbound, and Foundayo for $50/month starting July 1.

Semaglutide FDA Approval for Kidney Disease

FLOW trial: 24% lower risk of kidney failure, 29% lower cardiovascular death.

GLP-1 MASH Liver Approval

Semaglutide becomes the first GLP-1 approved for MASH.

Retatrutide TRIUMPH Phase 3 Results

TRIUMPH-1: 28.3% mean weight loss at 80 weeks.

Tirzepatide for Sleep Apnea

SURMOUNT-OSA: up to 63% lower sleep apnea severity.

Switching to Oral Orforglipron

Switching from injections to the oral orforglipron pill.

GLP-1s and Addiction

Large studies link GLP-1s to lower alcohol use disorder.

BPC-157 FDA Reclassification

The 2026 FDA reclassification of BPC-157, TB-500, and GHK-Cu.

The Five-Target Obesity Drug

A five-target molecule posting 40% weight loss in mice.